

Harold E Bays

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2352376/publications.pdf>

Version: 2024-02-01

40
papers

3,180
citations

361413

20
h-index

501196

28
g-index

42
all docs

42
docs citations

42
times ranked

3107
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. <i>New England Journal of Medicine</i> , 2010, 363, 245-256.	27.0	816
2	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , 2019, 380, 1022-1032.	27.0	529
3	Adiposopathy. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2461-2473.	2.8	358
4	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 593-603.	1.8	224
5	A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. <i>Clinical Therapeutics</i> , 2004, 26, 1758-1773.	2.5	171
6	Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. <i>Obesity</i> , 2014, 22, 1042-1049.	3.0	126
7	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100149.	3.0	87
8	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , 2021, 235, 104-112.	2.7	82
9	Adiposopathy, "Sick Fat," Ockham's Razor, and Resolution of the Obesity Paradox. <i>Current Atherosclerosis Reports</i> , 2014, 16, 409.	4.8	78
10	From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2009, 25, 671-681.	1.9	72
11	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 853-864.	2.6	71
12	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	1.5	70
13	Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating "Sick Fat" Through Improving Fat Function with Antidiabetes Therapies. <i>American Journal of Cardiology</i> , 2012, 110, 4B-12B.	1.6	56
14	Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and Telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 1, 100004.		37
15	Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 393-404.	1.5	36
16	Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 259-271.	0.9	36
17	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) <i>TJ ETQq1 1 0.78.4314 rgB2/Overl</i>		32
18	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. <i>Journal of Clinical Lipidology</i> , 2017, 11, 450-458.e1.	1.5	28

#	ARTICLE	IF	CITATIONS
19	Liraglutide 3.0mg for weight management: weight-loss dependent and independent effects. <i>Current Medical Research and Opinion</i> , 2017, 33, 225-229.	1.9	27
20	Licoglitflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. <i>Obesity</i> , 2020, 28, 870-881.	3.0	27
21	Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 265-277.	1.5	25
22	Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 3, 100026.		22
23	Assessment of the 1% of Patients with Consistent $\geq 15\%$ Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 175-180.	2.6	21
24	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	1.5	20
25	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
26	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100278.	3.0	14
27	Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 1, 100007.		14
28	Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100018.		13
29	Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100017.		11
30	Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100014.		11
31	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. <i>Journal of Clinical Lipidology</i> , 2017, 11, 929-937.	1.5	9
32	Ten things to know about ten imaging studies: A preventive cardiology perspective (ASPC top ten) <i>Overlock 10</i>	3.0	
33	Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100015.		9
34	Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 3, 100027.		8
35	Lorcaserin and metabolic disease: weight-loss dependent and independent effects. <i>Obesity Science and Practice</i> , 2018, 4, 499-505.	1.9	5
36	Obesity pillars roundtable: Phentermine “ Past, present, and future. , 2022, 3, 100024.		5

#	ARTICLE	IF	CITATIONS
37	Obesity Pillars Roundtable: Obesity and South Asians. , 2022, 1, 100006.		3
38	Obesity Pillars Roundtable: Obesity and Diversity. , 2022, 1, 100008.		1
39	Obesity Medicine Association (OMA): Nurse practitioner & physician assistants update. , 2022, 1, 100001.		1
40	Obesity Pillars Roundtable: Obesity and East Asians. , 2022, 2, 100011.		1